Transcatheter Aortic Valve Replacement for Bicuspid Aortic Stenosis With a Severely Calcified Raphe Using An Under-Sized SAPIEN 3 Valve: Sizing by the Circle Method and Deployment by the Pressure-Regulated Method.
Bicuspid aortic valve
Case report
TAVI
TAVR
Journal
Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
24
07
2022
revised:
17
08
2022
accepted:
18
08
2022
medline:
11
10
2023
pubmed:
29
8
2022
entrez:
28
8
2022
Statut:
ppublish
Résumé
Transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve stenosis is challenging, and the absence of established methods for sizing the bicuspid aortic valve (BAV) complicates TAVR. We report a case of successful TAVR for bicuspid aortic stenosis with a severely calcified raphe. We used an undersized SAPIEN 3 valve, with three safety measures based on assessment of structural characteristics, sizing by the circle method, and deployment of the valve by the pressure-regulated method.
Identifiants
pubmed: 36031540
pii: S1553-8389(22)00726-6
doi: 10.1016/j.carrev.2022.08.025
pii:
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
S149-S152Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Toyoaki Murohara received lecture fees from Bayer Pharmaceutical Co LTD, Daiichi Sankyo Co Ltd., Dainippon Sumitomo Pharma Co Ltd., Kowa Co Ltd., MSD, Mitsubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim Co Ltd., Novartis Pharma Kabushiki Kaisha, Pfizer Japan Inc., Sanofi-aventis, Takeda Pharmaceutical Co Ltd. Toyoaki Murohara received unrestricted research grants from Daiichi Sankyo Co Ltd., Dainippon Sumitomo Pharma Co Ltd., Kowa Co Ltd., MSD, Mitsubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim Co Ltd., Novartis Pharma Kabushiki Kaisha, Pfizer Japan Inc., Sanofi-aventis, Takeda Pharmaceutical Co Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co Ltd., Teijin Pharma Ltd. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.